News & analysis on the clinical development and manufacture of large molecule drugs
AMR: Emile Nuwaysir
By Ben Hargreaves
- Last updated on
Emile Nuwaysir has been appointed to the role of vice chairman at the Alliance for Regenerative Medicine (AMR). The organisation is an international multi-stakeholder advocacy group that promotes initiatives to improve access to regenerative medicines worldwide.
Nuwaysir will take on the role alongside his full-time role as CEO of BlueRock Therapeutics – an engineered cell therapy company that produces native therapies to restore or regenerate lost function to damaged or degenerated tissue.
Matt Patterson, who was formerly vice chairman, will now step up to the role of chairman.
Nuwaysir commented on his appointment, “As a direct result of ARM's past advocacy, these revolutionary therapies are developed more quickly, accelerating patient access to safe and effective products. I am honoured by this appointment, as these advanced cell and gene therapies represent the next generation of medicine by addressing the underlying causes of disease.”